ISPOR

Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing

Retrieved on: 
Thursday, May 25, 2023
Oncology, Data Management, Health, Technology, General Health, Pharmaceutical, Biotechnology, Risk, ISPOR, Medication, Lung cancer, Medicare, Patient, Diagnosis, Poster, International Society, Pharmaceutical industry

The posters, presented May 8-9, 2023, highlighted potential cost savings in both Medicare and commercially insured patient populations with use of the tests.

Key Points: 
  • The posters, presented May 8-9, 2023, highlighted potential cost savings in both Medicare and commercially insured patient populations with use of the tests.
  • The analyses estimated cost savings in a hypothetical population of 1 million patients in a US Medicare or commercial payer setting over a 2-year time horizon.
  • "These data presented at ISPOR solidifies the transformative potential of our Nodify CDT and Nodify XL2 tests," said Scott Hutton, CEO of Biodesix.
  • Our commitment is to pursue innovations that transform patient care while bringing economic balance to the healthcare system."

CCX appoints Blake Dark, former NHS chief negotiator, to advisory board

Retrieved on: 
Tuesday, May 16, 2023
Dark, Partnership, ISPOR, England, CCX, CADTH, Ecosystem, NHS, NICE, Software, Management, Pharmaceutical industry, Sanofi

ZUG, Switzerland and BOSTON, May 16, 2023 /PRNewswire-PRWeb/ -- CCX, the market access software leader, announced today that Blake Dark has joined the company's advisory board. With a deep understanding of both the constraints and possibilities in market access, Dark will advise on both the design of CCX's transformational platform and commercial strategy.

Key Points: 
  • Blake Dark, former NHS chief negotiator, joins other leaders from industry and payer to advise CCX as they build and deploy the technology stack for market access.
  • ZUG, Switzerland and BOSTON, May 16, 2023 /PRNewswire-PRWeb/ -- CCX, the market access software leader, announced today that Blake Dark has joined the company's advisory board.
  • "I'm very excited to support CCX and join such a prestigious group of advisors," said Blake Dark.
  • "I'm very pleased that Blake has joined the CCX advisory board.

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

Retrieved on: 
Tuesday, May 16, 2023
Neutropenia, Carcinoma, Medical Affairs Bureau, Providence St. Joseph Health, G1 Therapeutics, EMR, ISPOR, Pharmacoeconomics, Aplastic anemia, Patient, SCLC, RESEARCH, Bone marrow suppression, Risk, ECOG, Anemia, Diagnosis, Poster, Cornerstone, Therapy, Death, Thrombocytopenia, International Society, PARK, Medical imaging

“Chemotherapy remains an effective cornerstone treatment for patients with small cell lung cancer; unfortunately, chemotherapy-induced myelosuppression is a known common and debilitating complication associated with these cytotoxic regimens,” said Norman Nagl, Ph.D., Vice President of Medical Affairs at G1 Therapeutics.

Key Points: 
  • “Chemotherapy remains an effective cornerstone treatment for patients with small cell lung cancer; unfortunately, chemotherapy-induced myelosuppression is a known common and debilitating complication associated with these cytotoxic regimens,” said Norman Nagl, Ph.D., Vice President of Medical Affairs at G1 Therapeutics.
  • The poster, titled, “An Analysis of Patient Characteristics Associated With Myelosuppression Among Small Cell Lung Cancer Patients Treated in US Community Cancer Care Practices” is available in the scientific publications section of G1’s website.
  • Adult patients diagnosed with SCLC who received chemotherapy between 2016 and 2018 and had longitudinal laboratory data were included in this study.
  • In addition, multivariate logistic regressions were conducted to examine association between patient characteristics and risk of myelosuppression in each lineage (anemia, neutropenia, thrombocytopenia).

CADTH Honours 2 Leaders for Outstanding Contributions to Health Technology Assessment in Canada

Retrieved on: 
Tuesday, May 16, 2023
Faculty, Agency, University, Research design, ISPOR, The Ottawa Hospital, React, Faculty of Pharmacy, University of Lisbon, HTA, Research, University of Ottawa Heart Institute, Language, International Network of Health Promoting Hospitals and Health Services, Associate, Science, Creativity, Organization, Public health, Patient, School, ISCB Senior Scientist Award, COVID-19 Response Recognition Award, ICES, Chiang Mai University, Medical device, Management, Nursing, Pharmacy, CADTH

OTTAWA, ON, May 16, 2023 /CNW/ - Today, CADTH, Canada's drug and health technology agency, announced the recipients of its 2023 Recognition Awards.

Key Points: 
  • OTTAWA, ON, May 16, 2023 /CNW/ - Today, CADTH, Canada's drug and health technology agency, announced the recipients of its 2023 Recognition Awards.
  • These prizes honour individuals who are pushing the science of health technology assessment (HTA) forward, mentoring the next generation of leaders, and helping to grow Canada's reputation for excellence in the field.
  • Brian was a key member of the international joint task group convened by the International Network of Agencies for Health Technology Assessment to lead this work.
  • Dr. Kednapa Thavorn is at the forefront of this advancement in Canada, as both a methodologist and health economist.

Fujitsu conducts project with Takeda and National Cancer Center Japan to analyze and visualize of patient journey with ovarian cancer

Retrieved on: 
Friday, May 12, 2023
Insurance, Comment, Health, Takeda, ISPOR, Health Level 7, Takeda Pharmaceutical Company, Cancer, Research, Pharmacoeconomics, Organization, Platform, Patient, Physician, Data, Division, Informatics, National Cancer Center, Diagnosis, AI, HL7, Ovarian cancer, Environment, International Society, Pharmaceutical industry, Nursing, Medical imaging, Fujitsu

These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.

Key Points: 
  • These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.
  • This study was conducted based on a joint research agreement that Fujitsu concluded with Takeda and the National Cancer Center Japan in May 2021 with the aim of identifying clinical challenges that will contribute to improving the quality and therapeutic efficacy of personalized ovarian cancer treatment.
  • In the future, the platform will be able to extract patient medical data and convert it into HL7 FHIR(2).
  • It includes electronic medical record data, medical accounting data, health checkup data, patient registry data, and data obtained from wearable devices.

New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure

Retrieved on: 
Wednesday, May 10, 2023
Heart failure, Prevalence, Diabetes, Hospital, ISPOR, LVEF, NDA, Pharmacoeconomics, Life expectancy, Patient, Risk, PDUFA, Lexicon Pharmaceuticals, International Society, Satellite navigation device, Pharmaceutical industry

THE WOODLANDS, Texas, May 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that results of a new investigator-initiated economic analysis, based on results from the SOLOIST-WHF Phase 3 outcomes study of its investigational medicine sotagliflozin, were presented on May 9 at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting in Boston, Massachusetts.

Key Points: 
  • The researchers determined that sotagliflozin is a clinically and economically attractive medication and is cost-effective at commonly accepted willingness-to-pay thresholds in patients with diabetes and worsening heart failure.
  • Heart failure is the leading cause of hospitalization for Americans over the age of 65.
  • Patients with heart failure are at highest risk of having a repeat heart failure event in the first 30 days post-discharge, with 7% dying and 25% being rehospitalized within one month.
  • Lexicon’s NDA for sotagliflozin for the treatment of heart failure is on track for its May 27, 2023 PDUFA action date.

SwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women

Retrieved on: 
Wednesday, May 10, 2023
Research, Infectious Diseases, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, AMN, Hospital, Liver disease, ISPOR, AAN, Woman, American Academy, Pharmacy, Pharmacoeconomics, AAV, Standard of care, Patient, American Academy of Neurology, Therapy, Death, Moyamoya disease, International Society, Pharmaceutical industry, Health insurance, Medicare

SwanBio Therapeutics , a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women.

Key Points: 
  • SwanBio Therapeutics , a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women.
  • Adults with AMN experienced more comorbidities, including peripheral vascular disease (men: 4.6% vs. 0.9%; women: 2.2% vs. 0.5%), chronic pulmonary disease (men: 6.3% vs. 2.6%; women: 6.0% vs. 3.6%), and liver disease (men: 5.6% vs. 0.8%; women: 3.2% vs. 0.9%).
  • A significantly larger proportion of people living with AMN had at least one hospital admission (men: 32.0% vs. 6.1%; women: 23.2% vs. 7.2%).
  • Men living with AMN also utilized significantly more prescription medications (18.1 vs. 5.4 pharmacy fills per year).

Sanofi research demonstrates 9.3% reduction in all-cause healthcare resource utilization rates, including 23.5% decrease in hospitalization for Dario users

Retrieved on: 
Tuesday, May 9, 2023
Partnership, Diabetes, ISPOR, Food and Drug Administration, Research, Data analysis, Sanofi, Conditional sentence, Health, FDA, Digital health, Food, Medical imaging, Dario

NEW YORK, May 9, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the presentation of research at ISPOR 2023 demonstrating significant reductions in healthcare resource utilization for Dario users compared to non-users, the first study completed by Sanofi U.S. ("Sanofi") under its strategic agreement with Dario. ISPOR, the leading global conference for health economics and outcomes research, is being held May 7th – 10th in Boston.

Key Points: 
  • ISPOR, the leading global conference for health economics and outcomes research, is being held May 7th – 10th in Boston.
  • The study conducted by Sanofi and presented at ISPOR demonstrates a statistically significant 9.3% reduction in all-cause Heath Care Resource Utilization (HCRU), including a 23.5% reduction in hospitalizations, in Dario users after 12 months.
  • "We are incredibly proud of this new research demonstrating Dario's ability to potentially reduce health care utilization through a holistic, user-centric digital health solution.
  • This research is the first of several studies to be released based on this data analysis to demonstrate the impact of Dario on clinical, resource utilization and financial outcomes.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Abstract, EASL, Therapy, NASH, NAS, ISPOR, Obeticholic acid, NDA, Research, Non-alcoholic fatty liver disease, Meta-analysis, Different, Literature review, Breakthrough therapy, Evidence, Patient, Term Asset-Backed Securities Loan Facility, Institute for Clinical and Economic Review, Fibrosis, NHANES, Prevalence, ICER, Liver, Fatty liver disease, Loan, FDA, Epidemiology, Three Months, Treatment, Cirrhosis, Pharmaceutical industry, Medical imaging, Dietary supplement, Inflammation, Madrigal, Lipid

Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH trial

Key Points: 
  • Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH trial
    CONSHOHOCKEN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports first quarter 2023 financial results.
  • Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “In the first quarter of 2023, the Madrigal team made significant progress advancing our regulatory preparations, disease education initiatives, and market access strategy.
  • Additionally, we continue to execute against our clinical development objectives, and have completed enrollment of the MAESTRO-NASH trial.
  • Interest expense for the three month period ended March 31, 2023 was $2.3 million, compared to $0.0 million in the comparable prior year period.

Komodo Health Platform Powers 17 Cutting-Edge Health Economics and Outcomes Research Presentations at ISPOR 2023

Retrieved on: 
Monday, May 8, 2023
Software, Research, Professional Services, Pharmaceutical, Data Management, Venture Capital, Technology, Hospitals, Artificial Intelligence, Health Technology, Science, Health, Komodo, Duke University, Depression, ISPOR, COVID-19, Haemophilia, Genomics, Multiple sclerosis, Pharmacoeconomics, DSM-IV codes, Patient, Novo Nordisk, Janssen Pharmaceuticals, Mab, RWE, Government, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, International Society, Food, Prostate cancer, Pharmaceutical industry, Medical imaging

Komodo Health today announced that its real-world evidence (RWE) technology platform has been used to support 17 new health economics and outcomes research (HEOR) studies being presented at the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference.

Key Points: 
  • Komodo Health today announced that its real-world evidence (RWE) technology platform has been used to support 17 new health economics and outcomes research (HEOR) studies being presented at the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference.
  • Together, researchers representing Komodo Health, its customers, and its partners will present the results of research analyzing clinical and economic value across a wide range of therapeutic areas, including COVID-19, multiple sclerosis, prostate cancer, and more.
  • “The world’s top Life Sciences research teams are increasingly turning to Komodo’s Healthcare Map and real-world evidence applications to power their research strategies,” said Usha Periyanayagam, Head of Research and Analytics at Komodo Health.
  • Within the Komodo platform, users can perform comprehensive analytics, develop predictive models, and employ custom workflows to unlock a range of patient-centric insights.